Refining inflammatory myopathies incidence and characteristics: a quadruple source capture-recapture survey using 2017 ACR/EULAR criteria.

Date publication

mai 2023

Journal

Arthritis & rheumatology (Hoboken, N.J.)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LIPSKER Dan , Pr VELTEN Michel , Pr GOTTENBERG Jacques-Eric , Pr MARTIN Thierry , Pr GENY Bernard

Tous les auteurs :
Debrut L, Giannini M, Klein D, Spielmann L, Mertz P, Martin T, Nadaj-Pakleza A, Hirschi S, Nespola B, Lannes B, Terzic J, Hinschberger O, Dervieux B, Lipsker D, Arnaud L, Gottenberg JE, Kleinmann JF, Geny B, Séverac F, Velten M, Sibilia J, Meyer A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37192377

Résumé

Inflammatory myopathies (IM), characterized by muscle inflammation and weakness, are rare systemic diseases. Our previous study estimated an IM incidence rate of 7.98 cases/million/year (95% CI: [7.38-8.66]) and highlighted important variations that were likely due to methodological issues rather than true epidemiological differences. The aim of this study was to refine the incidence of IM, using the 2017 ACR/EULAR IM classification criteria and a quadruple source capture-recapture method during a 6-year period in Alsace (France), a 2-million-population region, benefiting from good access to healthcare and accredited IM referral centers.

Référence

Arthritis Rheumatol. 2023 05 16;: